Retrospective trial evaluates SLERPI's diagnostic and prognostic capabilities in SLE, indicating significant implications for flare risk assessment.
Objectives To evaluate the diagnostic performance of the SLE Risk Probability Index (SLERPI) in a European cohort and explore its potential prognostic utility for early flare risk stratification. Methods This retrospective study included 280 patients with physician-diagnosed SLE and 156 non-SLE controls from a tertiary centre. Diagnostic performance (sensitivity, specificity, and area under the curve [AUC]) of the SLERPI and the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria were assessed against physician diagnosis as the reference standard. Severe flares within 3 years of diagnosis were defined using the SELENA-SLEDAI Flare Index. Multivariable logistic regression was used to identify predictors of severe flare. Results SLERPI demonstrated a higher AUC than the 2019 EULAR/ACR criteria (0.967, 95% CI 0.950–0.984 vs 0.932, 95% CI 0.908–0.957; DeLong p = 0.0004) and greater specificity (97.4% vs 94.9%), whereas sensitivity (85.7% vs 87.1%) and negative predictive value (79.2% vs 80.4%) were slightly lower. Analysis of discordant classifications revealed that the SLERPI captured cutaneous-predominant presentations more effectively, while the EULAR/ACR criteria showed greater sensitivity for serositis-driven disease. Patients who developed a severe flare within 3 years had significantly higher baseline SLERPI scores ( p = 0.047). Youden’s J statistic identified a threshold of ≥10.2 points as potentially informative for severe flare risk stratification. In multivariable analysis, a model incorporating SLERPI constituent items identified proteinuria and serositis at diagnosis as independent predictors of severe flare (AUC 0.708, 95% CI 0.641-0.775); bootstrap internal validation yielded a lower, optimism-corrected AUC of 0.635 (95% CI 0.574-0.695). Conclusion SLERPI demonstrates high diagnostic accuracy in a single-centre retrospective Central European cohort. Exploratory analyses suggest that higher baseline SLERPI scores may be associated with an increased risk of early severe flares; however, these findings require external validation before prognostic use can be recommended.
No takes yet. Share an insight, caveat, or question.
Zoli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: